882 related articles for article (PubMed ID: 1379256)
1. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256
[TBL] [Abstract][Full Text] [Related]
2. Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men.
Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
J Clin Endocrinol Metab; 1993 Jan; 76(1):134-8. PubMed ID: 8421077
[TBL] [Abstract][Full Text] [Related]
3. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
[TBL] [Abstract][Full Text] [Related]
4. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.
Vittone J; Blackman MR; Busby-Whitehead J; Tsiao C; Stewart KJ; Tobin J; Stevens T; Bellantoni MF; Rogers MA; Baumann G; Roth J; Harman SM; Spencer RG
Metabolism; 1997 Jan; 46(1):89-96. PubMed ID: 9005976
[TBL] [Abstract][Full Text] [Related]
5. Responses of growth hormone (GH) and somatomedin-C to GH-releasing hormone in healthy aging men.
Pavlov EP; Harman SM; Merriam GR; Gelato MC; Blackman MR
J Clin Endocrinol Metab; 1986 Mar; 62(3):595-600. PubMed ID: 3080468
[TBL] [Abstract][Full Text] [Related]
6. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men.
Iranmanesh A; South S; Liem AY; Clemmons D; Thorner MO; Weltman A; Veldhuis JD
Eur J Endocrinol; 1998 Jul; 139(1):59-71. PubMed ID: 9703380
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study.
Bellantoni MF; Vittone J; Campfield AT; Bass KM; Harman SM; Blackman MR
J Clin Endocrinol Metab; 1996 Aug; 81(8):2848-53. PubMed ID: 8768841
[TBL] [Abstract][Full Text] [Related]
8. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy.
Vance ML; Kaiser DL; Martha PM; Furlanetto R; Rivier J; Vale W; Thorner MO
J Clin Endocrinol Metab; 1989 Jan; 68(1):22-8. PubMed ID: 2491864
[TBL] [Abstract][Full Text] [Related]
9. Sustained growth hormone (GH) and insulin-like growth factor I responses to prolonged high-dose twice-daily GH-releasing hormone stimulation in middle-aged and older men.
Veldhuis JD; Patrie JT; Frick K; Weltman JY; Weltman A
J Clin Endocrinol Metab; 2004 Dec; 89(12):6325-30. PubMed ID: 15579798
[TBL] [Abstract][Full Text] [Related]
10. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
[TBL] [Abstract][Full Text] [Related]
11. Oral arginine-lysine does not increase growth hormone or insulin-like growth factor-I in old men.
Corpas E; Blackman MR; Roberson R; Scholfield D; Harman SM
J Gerontol; 1993 Jul; 48(4):M128-33. PubMed ID: 8315224
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
Aloi JA; Gertz BJ; Hartman ML; Huhn WC; Pezzoli SS; Wittreich JM; Krupa DA; Thorner MO
J Clin Endocrinol Metab; 1994 Oct; 79(4):943-9. PubMed ID: 7962302
[TBL] [Abstract][Full Text] [Related]
13. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
[TBL] [Abstract][Full Text] [Related]
14. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study.
Jaffe CA; Turgeon DK; Friberg RD; Watkins PB; Barkan AL
J Clin Endocrinol Metab; 1995 Nov; 80(11):3321-6. PubMed ID: 7593445
[TBL] [Abstract][Full Text] [Related]
15. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Ionescu M; Frohman LA
J Clin Endocrinol Metab; 2006 Dec; 91(12):4792-7. PubMed ID: 17018654
[TBL] [Abstract][Full Text] [Related]
16. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
[TBL] [Abstract][Full Text] [Related]
17. Accelerated escape from GH autonegative feedback in midpuberty in males: evidence for time-delimited GH-induced somatostatinergic outflow in adolescent boys.
Richmond E; Rogol AD; Basdemir D; Veldhuis OL; Clarke W; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2002 Aug; 87(8):3837-44. PubMed ID: 12161519
[TBL] [Abstract][Full Text] [Related]
18. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
[TBL] [Abstract][Full Text] [Related]
19. Age and secretagogue type jointly determine dynamic growth hormone responses to exogenous insulin-like growth factor-negative feedback in healthy men.
Veldhuis JD; Weltman JY; Weltman AL; Iranmanesh A; Muller EE; Bowers CY
J Clin Endocrinol Metab; 2004 Nov; 89(11):5542-8. PubMed ID: 15531509
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
Bowers CY; Granda-Ayala R
Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
